Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $429 to $323.
Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $429 to $323.